Inclusion Criteria:
  1. Prior HSCT relapse beyond 6 months without active GVHD; systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 4 weeks
  2. De novo AML
  3. Transformed AML
  4. MDS with excess blasts (RAEB-2)
  5. MDS that is not a candidate for induction chemotherapy.
  6. Myeloproliferative neoplasms with blastic transformation
  7. Patients have exhausted standard therapeutic options
Exclusion Criteria:
  1. Prior solid organ transplantation
  2. Potentially curative therapy including hematopoietic cell transplant
  3. Prior treatment with CD123xCD3 or CLL1x3 bispecific agents, T cells expressing CD123 CAR or CLL1 CAR, or toxin-conjugated to CD123 or CLL1 antibodies.